Paris , 21 October 2021 - Ipsen , a global specialty-driven biopharmaceutical group, publishes its sales performance for the third quarter of 2021 and the year to date. Sales. | June 16, 2023
Supplemental New Drug Application submission based on the NAPOLI 3 Phase III trial1Approval would represent expansion of treatment options in an aggressive and difficult-to-treat cancer with few. | June 14, 2023
Supplemental New Drug Application submission based on the NAPOLI 3 Phase III trial1Approval would represent expansion of treatment options in an aggressive and difficult-to-treat cancer with few. | June 14, 2023
Ipsen shares are closing back in on major support levels around 106.8 EUR based on daily price data, which could offer attractive entry points. | June 1, 2023
REGULATED INFORMATION Description of the regulatory framework of the share repurchase programproposed by the Board of Directors to be approved at theCombined Shareholders’ Meeting. | May 31, 2023